Sanofi (NASDAQ:SNY) Given Consensus Rating of “Buy” by Analysts

Shares of Sanofi (NASDAQ:SNY) have received an average recommendation of “Buy” from the eleven analysts that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $62.6667.

SNY has been the topic of several research analyst reports. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Weiss Ratings reissued a “hold (c+)” rating on shares of Sanofi in a report on Monday. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Finally, JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th.

Sanofi Stock Up 2.3%

Sanofi stock opened at $50.28 on Wednesday. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.94 and a current ratio of 1.06. The firm’s 50-day simple moving average is $49.41 and its 200 day simple moving average is $49.25. The stock has a market cap of $123.46 billion, a PE ratio of 11.78, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.60 by $0.10. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The firm had revenue of $14.53 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter last year, the firm earned $2.25 EPS. The company’s quarterly revenue was down 7.5% compared to the same quarter last year. Research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Institutional Trading of Sanofi

Several hedge funds have recently made changes to their positions in SNY. Financial Consulate Inc. bought a new position in shares of Sanofi during the 3rd quarter worth $26,000. Ameritas Advisory Services LLC bought a new position in Sanofi during the second quarter worth about $28,000. Accent Capital Management LLC bought a new position in Sanofi during the first quarter worth about $29,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Sanofi in the third quarter worth about $29,000. Finally, Eastern Bank raised its position in shares of Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares during the period. 14.03% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.